Cancer prevalence and cancer screening in patients with acromegaly: a single center experience

Durmuş, Elif Tutku; Atmaca, Ayşegül; Çolak, Ramis; Durmuş, Buğra

doi:10.1007/s12020-022-03082-z

Cited by 6 publications

(4 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another study [13] included all patients diagnosed with cancer at least 4 years after acromegaly diagnosis. Five studies [14][15][16][17][18] excluded patients who developed cancer before acromegaly diagnosis. Three studies excluded patients whose cancers were diagnosed 6 [5], 5 [19], and 1 [20] year before the diagnosis of acromegaly.…”

Section: Organization Of Cancer Groupsmentioning

confidence: 99%

Risk of cancer in acromegaly patients: An updated meta-analysis and systematic review

Xiao,

Wang

et al. 2023

PLoS ONE

View full text Add to dashboard Cite

The incidence of cancer in acromegaly patients may be higher than that in the general population, although this has not been fully elucidated yet. This study analyzed the risk of various important types of cancer in acromegaly patients. The study was registered in INPLASY (registration number: INPLASY202340037). The PubMed, Web of Science, and EMBASE databases were searched for studies based on strict inclusion and exclusion criteria, from the time of database inception up to June 30, 2022. All observational studies of acromegaly patients with cancer were included, without language restrictions. We used the Newcastle–Ottawa scale (NOS) checklist to assess the quality of evidence. A meta-analysis revealed the relationship between acromegaly and cancer using the standardized incidence rates (SIRs) and 95% confidence intervals (CIs) retrieved from the included studies. Nineteen studies were included and analyzed. The overall incidence of cancer (SIR = 1.45, 95%CI = 1.20–1.75), as well as that of thyroid (SIR = 6.96, 95%CI = 2.51–19.33), colorectal and anal (SIR = 1.95, 95%CI = 1.32–2.87), brain and central nervous system (SIR = 6.14, 95%CI = 2.73–13.84), gastric (SIR = 3.09, 95%CI = 1.47–6.50), urinary (SIR = 2.66, 95%CI = 1.88–3.76), hematological (SIR = 1.89, 95%CI = 1.17–3.06), pancreatic and small intestine (SIR = 2.59, 95%CI = 1.58–4.24), and connective tissue (SIR = 3.15, 95%CI = 1.18–8.36) cancers, was higher among patients with acromegaly than among the general population. No association between acromegaly and hepatobiliary, respiratory, reproductive, skin, breast, or prostate cancer was observed. This study demonstrated that acromegaly patients have a modestly increased chance of cancer as compared to the general population. Risk factors for cancer need to be further explored to monitor patients with acromegaly at a high risk for cancer more carefully.

show abstract

Section: Organization Of Cancer Groupsmentioning

confidence: 99%

Risk of cancer in acromegaly patients: An updated meta-analysis and systematic review

Xiao,

Wang

et al. 2023

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Due to the prior lack of biochemical disease control and the impact of IGF-1 on cellular proliferation, elevated levels of GH and IGF-1 before the initiation of pasireotide could have contributed to pancreatic tumour growth. Epidemiological studies have demonstrated that GH and IGF-1 may exert influence on cancer pathogenesis by modulating cellular growth and apoptosis, potentially leading to an augmented predisposition to progression to an advanced stage promoting tumour growth, metastasis, and contributing to the development of therapy resistance [1,20].…”

Section: Discussionmentioning

confidence: 99%

“…Acromegaly is a rare disease characterized by increased secretion of growth hormone (GH) and insulin-like growth factor 1 (IGF-1). Most often, an increase in GH is caused by a pituitary adenoma [1]. Acromegaly may lead to cardiovascular, respiratory, endocrine, metabolic and musculoskeletal comorbidities.…”

Section: Introductionmentioning

confidence: 99%

“…The incidence of diseases associated with acromegaly depends on the increased secretion of GH and IGF-1, which are multifunctional factors regulating cell proliferation, differentiation, and apoptosis. These factors are important in tumourigenesis [1]. The diagnosis of acromegaly is confirmed based on clinical symptoms, increased serum IGF-1, and the lack of GH inhibition after glucose administration.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Coexistence of acromegaly and pancreatic adenocarcinoma — case study

Grzelak,

Rosiek,

Kos-Kudła

2024

Medical Research Journal

View full text Add to dashboard Cite

Acromegaly is a rare condition characterized by increased secretion of growth hormone (GH) and insulin-like growth factor 1 (IGF-1). This disease may predispose to the development of neoplasms. This study aims to present a case of a patient with acromegaly and coexisting pancreatic adenocarcinoma and to highlight the potential positive impact of somatostatin receptor ligands used in acromegaly treatment on the potential benefits when combined with conventional pancreatic adenocarcinoma therapy.

show abstract

Integration of big data analytics in the investigation of the relationship between acromegaly and cancer

Iglesias,

Arias,

López

et al. 2024

Endocrinología, Diabetes y Nutrición

View full text Add to dashboard Cite

Cancer prevalence and cancer screening in patients with acromegaly: a single center experience

Cited by 6 publications

References 53 publications

Risk of cancer in acromegaly patients: An updated meta-analysis and systematic review

Risk of cancer in acromegaly patients: An updated meta-analysis and systematic review

Coexistence of acromegaly and pancreatic adenocarcinoma — case study

Integration of big data analytics in the investigation of the relationship between acromegaly and cancer

Contact Info

Product

Resources

About